AU2021273072A1 - Certain chemical compositions and methods of use thereof - Google Patents

Certain chemical compositions and methods of use thereof Download PDF

Info

Publication number
AU2021273072A1
AU2021273072A1 AU2021273072A AU2021273072A AU2021273072A1 AU 2021273072 A1 AU2021273072 A1 AU 2021273072A1 AU 2021273072 A AU2021273072 A AU 2021273072A AU 2021273072 A AU2021273072 A AU 2021273072A AU 2021273072 A1 AU2021273072 A1 AU 2021273072A1
Authority
AU
Australia
Prior art keywords
alkyl
amino
compound
cycloalkyl
4alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021273072A
Other languages
English (en)
Inventor
Chun-Hao Huang
Andrei W. Konradi
Ko-Chuan LEE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Algen Biotechnologies Inc
Original Assignee
Algen Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Algen Biotechnologies Inc filed Critical Algen Biotechnologies Inc
Publication of AU2021273072A1 publication Critical patent/AU2021273072A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2021273072A 2020-05-15 2021-05-14 Certain chemical compositions and methods of use thereof Pending AU2021273072A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063025474P 2020-05-15 2020-05-15
US63/025,474 2020-05-15
PCT/US2021/032495 WO2021231892A1 (en) 2020-05-15 2021-05-14 Certain chemical compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
AU2021273072A1 true AU2021273072A1 (en) 2022-12-15

Family

ID=76270111

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021273072A Pending AU2021273072A1 (en) 2020-05-15 2021-05-14 Certain chemical compositions and methods of use thereof

Country Status (12)

Country Link
US (2) US11591322B2 (https=)
EP (1) EP4149941B1 (https=)
JP (1) JP2023526332A (https=)
KR (1) KR20230051127A (https=)
CN (1) CN116261561B (https=)
AU (1) AU2021273072A1 (https=)
BR (1) BR112022023199A2 (https=)
CA (1) CA3178813A1 (https=)
ES (1) ES3054109T3 (https=)
IL (1) IL298219A (https=)
MX (1) MX2022014356A (https=)
WO (1) WO2021231892A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3054109T3 (en) 2020-05-15 2026-01-29 Algen Biotechnologies Inc Certain chemical compositions and methods of use thereof
WO2023086417A1 (en) * 2021-11-11 2023-05-19 Algen Biotechnologies, Inc. Compounds and methods of use thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4932412A (en) 1986-12-18 1990-06-12 Immunomedics, Inc. Intraoperative and endoscopic tumor detection and therapy
EP1223952B1 (en) 1999-10-07 2008-04-16 Carlos Estuardo Aguilar-Cordova Methods for treatment of solid tumors and metastasis by gene therapy
WO2004110350A2 (en) 2003-05-14 2004-12-23 Torreypines Therapeutics, Inc. Compouds and uses thereof in modulating amyloid beta
WO2006071958A1 (en) 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
US8415381B2 (en) 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
WO2012101065A2 (en) * 2011-01-28 2012-08-02 Novartis Ag Pyrimidine biaryl amine compounds and their uses
WO2012101063A1 (en) * 2011-01-28 2012-08-02 Novartis Ag N-acyl pyridine biaryl compounds and their uses
CN103339110A (zh) * 2011-01-28 2013-10-02 诺瓦提斯公司 作为cdk9抑制剂的取代的杂-联芳基化合物及其用途
WO2012101066A1 (en) 2011-01-28 2012-08-02 Novartis Ag Pyridine biaryl amine compounds and their uses
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
EP3126525B1 (en) 2014-04-04 2020-02-19 Memorial Sloan-Kettering Cancer Center Method and kits for identifying of cdk9 inhibitors for the treatment of cancer
NZ734082A (en) 2015-01-20 2019-01-25 Boehringer Ingelheim Animal Health Usa Inc Anthelmintic compounds, compositions and method of using thereof
PL3429591T3 (pl) 2016-03-16 2023-07-17 Kura Oncology, Inc. Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania
EP3874045A4 (en) 2018-10-31 2022-09-07 The Regents of The University of California Methods and kits for identifying cancer treatment targets
CN114025772A (zh) 2019-04-24 2022-02-08 纪念斯隆凯特琳癌症中心 用于治疗ras突变体癌症的组合物和方法
JP7677914B2 (ja) 2019-06-21 2025-05-15 アルゲン バイオテクノロジーズ，インク． 標的遺伝子を特定するための方法およびシステム
EP4126918A4 (en) 2020-03-31 2024-05-29 The Regents of the University of California COMPOSITIONS AND METHODS FOR IDENTIFYING HOST CELL TARGET PROTEINS FOR THE TREATMENT OF RNA VIRUS INFECTIONS
ES3054109T3 (en) 2020-05-15 2026-01-29 Algen Biotechnologies Inc Certain chemical compositions and methods of use thereof
EP4185867A4 (en) 2020-07-22 2024-08-07 Algen Biotechnologies, Inc. Methods and systems for determining drug effectiveness
WO2023086417A1 (en) 2021-11-11 2023-05-19 Algen Biotechnologies, Inc. Compounds and methods of use thereof

Also Published As

Publication number Publication date
CN116261561A (zh) 2023-06-13
US20220289725A1 (en) 2022-09-15
US20230295135A1 (en) 2023-09-21
EP4149941A1 (en) 2023-03-22
CA3178813A1 (en) 2021-11-18
US12264152B2 (en) 2025-04-01
BR112022023199A2 (pt) 2023-04-04
KR20230051127A (ko) 2023-04-17
ES3054109T3 (en) 2026-01-29
IL298219A (en) 2023-01-01
US11591322B2 (en) 2023-02-28
CN116261561B (zh) 2025-10-31
JP2023526332A (ja) 2023-06-21
MX2022014356A (es) 2023-03-09
WO2021231892A1 (en) 2021-11-18
EP4149941B1 (en) 2025-09-03

Similar Documents

Publication Publication Date Title
US11434232B2 (en) ATR inhibitor and application thereof
CN109152784B (zh) 经取代的menin-mll抑制剂及使用方法
US20210346382A1 (en) BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment
US20210015764A1 (en) Methods of reducing inflammation of the digestive system with inhibitors of hif-2- alpha
ES2664794T3 (es) Inhibidores de ERK y métodos de uso
EP4289835A1 (en) Cdk inhibitor
JP2020515559A (ja) Ｃｄ７３阻害剤とその使用
US20240316022A1 (en) Indazole compounds
RS62713B1 (sr) Terapeutske kombinacije btk inhibitora i bcl-2 inhibitora
US12264152B2 (en) Certain chemical compositions and methods of use thereof
ES3056658T3 (en) Pyridinone-based epigenetic modifiers and uses thereof
US20190192521A1 (en) Methods of Treating Arid1A-Mutated Cancers With HDAC6 Inhibitors and EZH2 Inhibitors
US20190209591A1 (en) Therapeutic Combinations of a Proteasome Inhibitor and a BTK Inhibitor
TW201823246A (zh) Cdk4/6抑制劑
JP7822308B2 (ja) 固形腫瘍の処置のための組成物
WO2024220866A1 (en) Novel aminopyrimidine derivatives as cyclin-dependent kinase inhibitors
JP2023510865A (ja) 血管脂肪腫の処置のための組成物
WO2023086417A1 (en) Compounds and methods of use thereof
US20200352915A1 (en) Car activator agents for cyclophosphamide-based treatments of cancer
US20230159569A1 (en) Dual hdac6/proteasome inhibitors, and methods of use thereof
US20240317777A1 (en) Novel macrocyclic aminopyrazole compounds as cdk2 inhibitors
EA052538B1 (ru) Производное сложного эфира пиразолзамещенного циклопентанола и его применение